|
 |
mequinolThis page contains recent news articles, when available, and an overview of mequinol but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.Mequinol and Tretinoin (MEC-kwin-all and TRET-i-noyn ) is used to treat areas of the skin that have become darker after repeated exposure to the sun. ... Free with registration - USP DI-Volume II, Advice for the... - AccessMyLibrary.com … Shows Favorable Results of Solage(R) (mequinol 2%, tretinoin... - Jan 12, 2007 Currently, Solage(R) (mequinol 2%, tretinoin 0.01%) Topical Solution is the only combination product approved in the United States for the treatment of ... Genetic Engineering News - Genetic Engineering News (press release) Mequinol and Tretinoin (Topical).(Drug overview) - May 1, 2006 Mequinol and Tretinoin (MEC-kwin-all and TRET-i-noyn ) is used to treat areas of the skin that have become darker after repeated exposure to the sun. ... Free with registration - USP DI-Volume II, Advice for the... - AccessMyLibrary.com Solar Lentigines; Mequinol 2%/tretinoin 0.01% treatment superior to … - Feb 7, 2005 2005 FEB 7 - (NewsRx.com & NewsRx.net) -- Mequinol 2%/tretinoin 0.01% solution is safe and effective for the treatment of solar lentigines. ... Pay-Per-View - Clinical Trials Week - Factiva, from Dow Jones Derm Research Inc. Mequinol 2%/tretinoin 0.01% treatment superior to ... - Feb 9, 2005 2005 FEB 9 - (NewsRx.com & NewsRx.net) -- Mequinol 2%/tretinoin 0.01% solution is safe and effective for the treatment of solar lentigines. ... Pay-Per-View - Biotech Week - Factiva, from Dow Jones Barrier Therapeutics Receives FDA Approval for Solage(R) Topical … - May 3, 2007 Barrier Therapeutics currently markets Solage(R) (mequinol 2%, tretinoin 0.01%) Topical Solution in the United States where it is indicated for the ... Genetic Engineering News - Genetic Engineering News (press release) Barrier Therapeutics Launches Denavir in Canada - Aug 23, 2006 ...the growth of unwanted facial hair in women and Solage ® (mequinol 2%, ... Ointment and Solage ® (mequinol 2.0%, tretinoin 0.01%) Topical Solution. ... marketwire.com Barrier Therapeutics to Present at the 19th Annual Roth Capital... - Feb 15, 2007 ...for diaper dermatitis complicated by documented candidiasis; and Solage(R) (mequinol 2.0%, tretinoin 0.01%) Topical Solution, for solar lentigines. ... Genetic Engineering News - Genetic Engineering News (press release) Barrier Therapeutics acquires rights to liver-spots treatment - Feb 7, 2005 Solage, which contains mequinol and trentinoin, is used to treat solar lentigines -- a common condition also known as age spots or liver spots. ... Philadelphia Business Journal Ventiv Health Announces Marketing Agreement with Barrier Therapeutics. - May 2, 2005 The Company currently markets Solage(R) (mequinol 2%, tretinoin 0.01%) Topical Solution for the treatment of solar lentigines in the US, a common condition ... $4.95 - PR Newswire - ECNext Barrier Therapeutics Inc acquires Moreland Enterprises-Solage from … - Feb 7, 2005 January ##, #### Barrier Therapeutics, Inc. announced that Currently, Solage (mequinol #%, tretinoin #.##…in Nails. #/##/#### -- Barrier Therapeutics to ... Pay-Per-View - deals - Alacra Store Best practices in: emerging treatment options for postinflammatory … - Oct 1, 2007 Recent clinical investigation of the combination solution of mequinol 2% and tretinoin 0.01% ... Clinical Trial of Topical Mequinol + Tretinoin in PIH. ... $4.95 - Skin & Allergy News - ECNext Combined Tx may improve male melasma.(Dermatologic Therapy) | … - Mar 1, 2007 ..."There are no previous reports of using mequinol in the treatment of melasma in women or men," noted Dr. Keeling, who presented the data on behalf of Dr. ... Pay-Per-View - Skin & Allergy News - HighBeam Research Melasma, undertreated in men, clears with topical solution.(Skin … - Feb 15, 2007 ..."There are no previous reports of using mequinol in the treatment of melasma in women or men," he said. Dr. Keeling presented the data on behalf of Dr. ... Pay-Per-View - Family Practice News - HighBeam Research Press Release: Barrier Therapeutics Acquires US and Canadian Rights... - Feb 7, 2005 Treatment of solar lentigines Mequinol 2%/tretinoin 0 ... solution for the ... The depigmenting agent should ... apply mequinol/ tretinoin to the solar ... Pay-Per-View - PR Newswire - HighBeam Research Barrier Therapeutics Receives Regulatory Approval to Market Xolegel... - Mar 8, 2007 ...for diaper dermatitis complicated by documented candidiasis; and Solage ® (mequinol 2.0%, tretinoin 0.01%) Topical Solution, for solar lentigines. ... ccnmatthews.com Wrinkles Blemishes - Wrinkles Health Information - NY Times Health - Dec 30, 2008 Tretinoin (Retin A) alone, or in combination with Mequinol (Solag). Tretinoin is related to vitamin A, and is also effective in treating wrinkles. ... New York Times Factiva Search - Feb 7, 2005 Solar Lentigines; Mequinol 2%/tretinoin 0.01% treatment superior to hydroquinone 3 ... 2005 FEB 7 - (NewsRx.com & NewsRx.net) -- Mequinol 2%/tretinoin 0.01% ... Pay-Per-View - Pharma Business Week - Factiva, from Dow Jones Article: Combo therapy may be hydroquinone alternative.(Clinical... - Apr 1, 2007 MAUI, HAWAII -- Combination therapy with mequinol 2% and tretinoin 0.01% solution was slightly more effective... Pay-Per-View - Skin & Allergy News - HighBeam Research Bloomberg Printer-Friendly Page - Mar 17, 2008 ...for diaper dermatitis complicated by documented candidiasis; and Solage(r) (mequinol 2.0%, tretinoin 0.01%) Topical Solution, for solar lentigines. ... Bloomberg Factiva Search - Feb 12, 2005 Solar Lentigines; Mequinol 2%/tretinoin 0.01% treatment superior to hydroquinone ... 2005 FEB 12 - (NewsRx.com & NewsRx.net) -- Mequinol 2%/tretinoin 0.01% ... Pay-Per-View - Obesity, Fitness & Wellness Week - Factiva, from Dow Jones Barrier Therapeutics Announces Third Quarter 2006 Financial Results - Oct 31, 2006 Vusion(TM) (0.25% miconazole nitrate, 15% zinc oxide, 81.35% white petrolatum) Ointment and Solage® (mequinol 2.0%, tretinoin 0.01%) Topical Solution. ... CNNMoney.com Factiva Search - Feb 8, 2005 Solar Lentigines; Mequinol 2%/tretinoin 0.01% treatment superior to hydroquinone 3 ... 2005 FEB 8 - (NewsRx.com & NewsRx.net) -- Mequinol 2%/tretinoin 0.01% ... Pay-Per-View - Science Letter - Factiva, from Dow Jones SmallCapReview - Small Cap Stocks on the Move - BTRX, MGI - Jun 23, 2008 ...for diaper dermatitis complicated by documented candidiasis; and Solage(r) (mequinol 2.0%, tretinoin 0.01%) Topical Solution, for solar lentigines. ... TransWorldNews - TransWorldNews (press release) Barrier Therapeutics to Present at the CE Unterberg, Towbin Emerging ... - Jul 5, 2006 ...(0.25% miconazole nitrate, 15% zinc oxide, and 81.35% white petrolatum) Ointment and Solage(R) (mequinol 2.0% and tretinoin 0.01%) Topical Solution. ... Genetic Engineering News - Genetic Engineering News (press release) Barrier Therapeutics Introduces Dual-Component Xolegel CorePak(TM) … - Jul 28, 2008 ...for diaper dermatitis complicated by documented candidiasis; and Solage(R) (mequinol 2.0%, tretinoin 0.01%) Topical Solution, for solar lentigines. ... RedOrbit Barrier Therapeutics Announces 2008 Financial Guidance and Updates … - Jan 7, 2008 ...for diaper dermatitis complicated by documented candidiasis; and Solage® (mequinol 2.0%, tretinoin 0.01%) Topical Solution, for solar lentigines. ... marketwire.com Barrier Therapeutics Receives FDA Approval of Xolegel(TM) Gel for the... - Jul 28, 2006 Vusion(TM) (0.25% miconazole nitrate, 15% zinc oxide, 81.35% white petrolatum) Ointment and Solage(R) (mequinol 2.0%, tretinoin 0.01%) Topical Solution. ... Genetic Engineering News - Genetic Engineering News (press release) Vusion Baby Bottom Line Report - Jun 17, 2008 ...for diaper dermatitis complicated by documented candidiasis; and Solage(R) (mequinol 2.0%, tretinoin 0.01%) Topical Solution, for solar lentigines. ... RedOrbit Barrier Therapeutics Announces Submission of Voluntary Dismissal of … - Nov 10, 2006 Vusion(TM) (0.25% miconazole nitrate, 15% zinc oxide, 81.35% white petrolatum) Ointment and Solage(R) (mequinol 2.0%, tretinoin 0.01%) Topical Solution. ... Genetic Engineering News - Genetic Engineering News (press release) Barrier Therapeutics to Participate in the 2006 RBC Capital Markets … - Dec 6, 2006 Vusion(TM) (0.25% miconazole nitrate, 15% zinc oxide, 81.35% white petrolatum) Ointment and Solage(R) (mequinol 2.0%, tretinoin 0.01%) Topical Solution. ... Genetic Engineering News - Genetic Engineering News (press release) OTCPicks.com Daily Market Movers Digest Midday Report - Jun 23, 2008 ...for diaper dermatitis complicated by documented candidiasis; and Solage® (mequinol 2.0%, tretinoin 0.01%) Topical Solution, for solar lentigines. ... TransWorldNews - TransWorldNews (press release) Barrier Therapeutics to Present at the European Academy of Dermatology... - Oct 5, 2006 Vusion(TM) (0.25% miconazole nitrate, 15% zinc oxide, 81.35% white petrolatum) Ointment and Solage(R) (mequinol 2.0%, tretinoin 0.01%) Topical Solution. ... Genetic Engineering News - Genetic Engineering News (press release) Other News To Note - Jun 23, 2008 Vusion (miconazole nitrate, zinc oxide and white petrolatum) ointment for diaper dermatitis complicated by candidiasis and Solage (mequinol, ... TMC Net Barrier Therapeutics to Present at the CIBC World Markets Annual … - Apr 5, 2007 ...for diaper dermatitis complicated by documented candidiasis; and Solage(R) (mequinol 2.0%, tretinoin 0.01%) Topical Solution, for solar lentigines. ... Genetic Engineering News - Genetic Engineering News (press release) Stiefel Laboratories Announces Expiration of Hart-Scott-Rodino... - Jul 29, 2008 ...for diaper dermatitis complicated by documented candidiasis; and Solage(R) (mequinol 2.0%, tretinoin 0.01%) Topical Solution, for solar lentigines. ... Lifescience-online Barrier Therapeutics to Present Data on Solage(R) and Sebazole(TM) at... - Jul 27, 2006 ...(0.25% miconazole nitrate, 15% zinc oxide, and 81.35% white petrolatum) Ointment and Solage(R) (mequinol 2.0% and tretinoin 0.01%) Topical Solution. ... Genetic Engineering News - Genetic Engineering News (press release) Barrier Therapeutics Announces Azoline (Pramiconazole) Dose Ranging … - Mar 27, 2007 ...for diaper dermatitis complicated by documented candidiasis; and Solage(R) (mequinol 2.0%, tretinoin 0.01%) Topical Solution, for solar lentigines. ... Genetic Engineering News - Genetic Engineering News (press release) Barrier Therapeutics to Release Second Quarter 2006 Financial Results... - Aug 7, 2006 Vusion(TM) (0.25% miconazole nitrate, 15% zinc oxide, 81.35% white petrolatum) Ointment and Solage(R) (mequinol 2.0%, tretinoin 0.01%) Topical Solution. ... prnewswire.com Barrier Therapeutics Announces Liarozole Phase 2/3 Study Results in … - Jun 14, 2007 ...for diaper dermatitis complicated by documented candidiasis; and Solagé® (mequinol 2.0%, tretinoin 0.01%) Topical Solution, for solar lentigines. ... marketwire.com Barrier Therapeutics Submission for Zimycan(TM) Deemed a Complete … - Oct 12, 2005 The Company currently markets Solagé® (mequinol 2%, tretinoin 0.01%) Topical Solution in the US and Canada for the treatment of solar lentigines, ... Web Services Journal - Web Services Journal Barrier Therapeutics to Present at the Natixis Bleichroeder Hidden... - Oct 1, 2007 ...for diaper dermatitis complicated by documented candidiasis; and Solagé® (mequinol 2.0%, tretinoin 0.01%) Topical Solution, for solar lentigines. ... marketwire.com Steifel acquires Barrier in $145M deal. - Jun 30, 2008 ...petrolatum) for diaper dermatitis complicated by documented candidiasis; and Solage (mequinol/tretinoin) Topical Solution for solar lentigines. ... $9.94 - Pharma Marketletter - Alacra Store BARRIER ACQUIRES VANIQA CANADIAN DISTRIBUTION RIGHTS. - Aug 1, 2005 The company currently markets Solag(r) (mequinol 2%, tretinoin 0.01%) Topical Solution in the US and Canada for the treatment of solar lentigines, ... Entrepreneur Barrier Therapeutics to Present at the Bank of America 2007 Health... - May 24, 2007 ...for diaper dermatitis complicated by documented candidiasis; and Solage(R) (mequinol 2.0%, tretinoin 0.01%) Topical Solution, for solar lentigines. ... Genetic Engineering News - Genetic Engineering News (press release) Barrier Therapeutics to Release Second Quarter 2006 Financial Results... - Aug 2, 2006 Vusion(TM) (0.25% miconazole nitrate, 15% zinc oxide, 81.35% white petrolatum) Ointment and Solage(R) (mequinol 2.0%, tretinoin 0.01%) Topical Solution. ... $4.95 - PR Newswire - ECNext Drug/Medical Device Report Barrier Therapeutics, Inc. (BTRX) - Aug 2, 2008 Solage (Tretinoin/Mequinol). Solar Lentigines (Age/Sun. Spots). Erythema, Burning,. Stinging/Tingling,. Desquamation, Pruritus. Approved ... $70.00 - Revere - Alacra Store Barrier Therapeutics Announces Third Quarter 2005 Financial Results - Nov 1, 2005 The Company currently markets Solagé® (mequinol 2%, tretinoin 0.01%) Topical Solution in the US and Canada for the treatment of solar lentigines, ... Web Services Journal - Web Services Journal PRESS RELEASE: Barrier Therapeutics Announces Promising Results … - Oct 19, 2007 ...for diaper dermatitis complicated by documented candidiasis; and Solagé® (mequinol 2.0%, tretinoin 0.01%) Topical Solution, for solar lentigines. ... FierceBiotech Company Profile Report - Aug 2, 2008 Solage (Tretinoin/Mequinol). Lesion/Scaling Disorders. Dermatitis. Seborrheic (Dandruff). Antifungal Agents. Imidazoles ... $50.00 - Revere - Alacra Store Combination approach moving from trend to norm.(Special Report: … - Jul 1, 2006 In recent months, newer agents, such as the topical mequinol/tretinoin solution for solar lentigines, as well as Botox (Allergan) and an increasing variety ... $4.95 - Dermatology Times - ECNext Barrier Therapeutics Reports Positive Phase 2a Data for Oral Rambazole... - Sep 19, 2005 The Company currently markets Solagé® (mequinol 2%, tretinoin 0.01%) Topical Solution in the US and Canada for the treatment of solar lentigines, ... Web Services Journal - Web Services Journal Barrier Therapeutics Announces Issuance of Xolegel(TM) Patent - Feb 20, 2007 ...for diaper dermatitis complicated by documented candidiasis; and Solagé® (mequinol 2.0%, tretinoin 0.01%) Topical Solution, for solar lentigines. ... Web Services Journal - Web Services Journal Company Profile Report - Aug 2, 2008 Solage (Tretinoin/Mequinol). Lesion/Scaling Disorders. Dermatitis. Seborrheic (Dandruff). Antifungal Agents. Imidazoles ... $50.00 - Revere Reports - Revere Business Update; Barrier Therapeutics launches Denavir in Canada - Sep 26, 2006 ...slowing the growth of unwanted facial hair in women and Solage (mequinol 2%, tretinoin 0.01%) Topical Solution for the treatment of solar lentigines, ... Pay-Per-View - Life Science Weekly - Factiva, from Dow Jones Barrier gains US/Canadian rights to Solage topical solution.(Barrier ... - Feb 14, 2005 US firm Barrier Therapeutics has announced the acquisition of the US and Canadian rights to Solage (mequinol 2%, tretinoin 0.01%) Topical Solution from ... Free with registration - Pharma Marketletter - AccessMyLibrary.com Barrier Therapeutics Announces Positive Phase 2a Data for Oral... - Jan 17, 2007 81.35% white petrolatum) Ointment, for diaper dermatitis complicated by candidiasis; and Solage(R) (mequinol 2.0%, tretinoin 0.01%) Topical Solution, ... RedOrbit Barrier Therapeutics Completes Patient Enrollment for Pivotal Phase 3... - Sep 28, 2007 ...for diaper dermatitis complicated by documented candidiasis; and Solagé® (mequinol 2.0%, tretinoin 0.01%) Topical Solution, for solar lentigines. ... marketwire.com Barrier Therapeutics to Present at Investor Conferences During … - Aug 27, 2007 ...for diaper dermatitis complicated by documented candidiasis; and Solagé® (mequinol 2.0%, tretinoin 0.01%) Topical Solution, for solar lentigines. ... marketwire.com Barrier Therapeutics Completes $31.9 Million Registered Direct... - Sep 27, 2007 ...for diaper dermatitis complicated by documented candidiasis; and Solagé® (mequinol 2.0%, tretinoin 0.01%) Topical Solution, for solar lentigines. ... marketwire.com Barrier Therapeutics Introduces New Xolegel Duo TM Offering at the … - Aug 2, 2007 ...for diaper dermatitis complicated by documented candidiasis; and Solage® (mequinol 2.0%, tretinoin 0.01%) Topical Solution, for solar lentigines. ... marketwire.com Barrier Therapeutics to Present at the 2007 Morgan Stanley Global … - Apr 26, 2007 ...for diaper dermatitis complicated by documented candidiasis; and Solage(R) (mequinol 2.0%, tretinoin 0.01%) Topical Solution, for solar lentigines. ... Genetic Engineering News - Genetic Engineering News (press release) Barrier Therapeutics to Present at the SIGnificant Investment Options... - Feb 22, 2007 ...for diaper dermatitis complicated by documented candidiasis; and Solage(R) (mequinol 2.0%, tretinoin 0.01%) Topical Solution, for solar lentigines. ... Genetic Engineering News - Genetic Engineering News (press release) Barrier Therapeutics to Release First Quarter 2007 Financial Results... - May 10, 2007 ...for diaper dermatitis complicated by documented candidiasis; and Solage(R) (mequinol 2.0%, tretinoin 0.01%) Topical Solution, for solar lentigines. ... Genetic Engineering News - Genetic Engineering News (press release) Barrier Therapeutics Establishes $12 Million Credit Facility - Jun 29, 2007 ...for diaper dermatitis complicated by documented candidiasis; and Solagé® (mequinol 2.0%, tretinoin 0.01%) Topical Solution, for solar lentigines. ... Web Services Journal - Web Services Journal Barrier Therapeutics Announces Agreement to Co-Promote Vusion(TM) … - Mar 6, 2007 ...for diaper dermatitis complicated by documented candidiasis; and Solagé® (mequinol 2.0%, tretinoin 0.01%) Topical Solution, for solar lentigines. ... Web Services Journal - Web Services Journal Barrier Therapeutics Introduces New 50g-Size Tube of Vusion(R) … - Jun 6, 2007 ...for diaper dermatitis complicated by documented candidiasis; and Solage(R) (mequinol 2.0%, tretinoin 0.01%) Topical Solution, for solar lentigines. ... Genetic Engineering News - Genetic Engineering News (press release) Barrier Therapeutics to Raise $31.9 Million in Registered Direct... - Sep 24, 2007 ...for diaper dermatitis complicated by documented candidiasis; and Solagé® (mequinol 2.0%, tretinoin 0.01%) Topical Solution, for solar lentigines. ... marketwire.com Barrier Therapeutics (BRTX) Reports Positive Findings for Solagé... - Jan 12, 2007 Barrier Therapeutics currently markets Solagé® (mequinol 2%, tretinoin 0.01%) Topical Solution in the United States where it is indicated for the treatment ... StreetInsider.com - StreetInsider.com (subscription) BARRIER REPORTS POSITIVE PHASE 2A DATA FOR ORAL … - Nov 1, 2005 The company currently markets Solag(r) (mequinol 2%, tretinoin 0.01%) Topical Solution in the US and Canada for the treatment of solar lentigines, ... Free with registration - Biotech Business - AccessMyLibrary.com Therapeutics, Inc. vs. Current Events. - Jun 15, 2007 ...for diaper dermatitis complicated by documented candidiasis; and Solage (mequinol 2.0%, tretinoin 0.01%) Topical Solution, for solar lentigines. ... Free with registration - M2 Presswire - AccessMyLibrary.com Barrier Therapeutics to Release Third Quarter 2007 Financial Results... - Oct 30, 2007 ...for diaper dermatitis complicated by documented candidiasis; and Solage(R) (mequinol 2.0%, tretinoin 0.01%) Topical Solution, for solar lentigines. ... Genetic Engineering News - Genetic Engineering News (press release) Barrier Therapeutics to Present at the 25th Annual JPMorgan Healthcare... - Jan 3, 2007 81.35% white petrolatum) Ointment, for diaper dermatitis complicated by candidiasis; and Solage(R) (mequinol 2.0%, tretinoin 0.01%) Topical Solution, ... Genetic Engineering News - Genetic Engineering News (press release) Barrier Therapeutics to Release Second Quarter 2007 Financial Results... - Aug 7, 2007 ...for diaper dermatitis complicated by documented candidiasis; and Solage(R) (mequinol 2.0%, tretinoin 0.01%) Topical Solution, for solar lentigines. ... Genetic Engineering News - Genetic Engineering News (press release) Barrier Therapeutics Appoints Dr. Braham Shroot, Dermatology Expert,... - May 16, 2007 ...for diaper dermatitis complicated by documented candidiasis; and Solagé® (mequinol 2.0%, tretinoin 0.01%) Topical Solution, for solar lentigines. ... Web Services Journal - Web Services Journal Barrier Therapeutics Announces Third Quarter 2007 Financial Results - Oct 30, 2007 ...for diaper dermatitis complicated by documented candidiasis; and Solagé® (mequinol 2.0%, tretinoin 0.01%) Topical Solution, for solar lentigines. ... marketwire.com Press Release: Barrier Therapeutics to Release Second Quarter 2006 … - Aug 2, 2006 Vusion(TM) (0.25% miconazole nitrate, 15% zinc oxide, 81.35% white petrolatum) Ointment and Solage(R) (mequinol 2.0%, tretinoin 0.01%) Topical Solution. ... Pay-Per-View - PR Newswire - HighBeam Research Drug/Medical Device Report Barrier Therapeutics, Inc. (BTRX) - Aug 2, 2008 Solage (Tretinoin/Mequinol). Solar Lentigines (Age/Sun. Spots). Erythema, Burning,. Stinging/Tingling,. Desquamation, Pruritus. Approved ... $70.00 - Revere Reports - Revere Competitors by Product Report - Aug 2, 2008 Products:. Solage (Tretinoin/Mequinol). Allergan, Inc. (AGN) Products:. Avage (Tazarotene) Cream. Johnson & Johnson (JNJ) Products:. Renova (Tretinoin) ... $75.00 - Revere - Alacra Store Barrier Therapeutics to Present at the Roth Capital Partners 17th... - Feb 16, 2005 The Company currently markets Solage(R) (mequinol 2%, tretinoin 0.01%) Topical Solution for the treatment of solar lentigines in the US, a common condition ... $4.95 - PR Newswire - ECNext Personnel; Pharmaceutical firm names three new additions to commercial... - Mar 14, 2005 ...now that we have acquired the marketed product Solage (mequinol 2%, tretinoin 0.01%) Topical Solution and as we prepare for the launch of Zimycan, ... Pay-Per-View - Health & Medicine Week - Factiva, from Dow Jones Reviewing Barrier Therapeutics Inc. Against the Current Markets. - Feb 13, 2007 ...for diaper dermatitis complicated by documented candidiasis; and Solage(R) (mequinol 2.0%, tretinoin 0.01%) Topical Solution, for solar lentigines. ... $4.95 - M2 Presswire - ECNext Barrier gets North American rights for skin treatment - Feb 9, 2005 Solage contains two active ingredients, mequinol and trentinoin. In the US, the product is indicated for the treatment of solar lentigines, commonly known ... Pay-Per-View - Datamonitor News and Comment - Factiva, from Dow Jones Business Update; Dermatology firm acquires US, Canadian rights to … - Mar 7, 2005 ...announced the acquisition of the US and Canadian rights to Solage (mequinol 2%, tretinoin 0.01%) Topical Solution from Moreland Enterprises Limited. ... Pay-Per-View - Pharma Business Week - Factiva, from Dow Jones Press Release: Reviewing Barrier Therapeutics Inc. Against the... - Feb 13, 2007 ...for diaper dermatitis complicated by documented candidiasis; and Solage(R) (mequinol 2.0%, tretinoin 0.01%) Topical Solution, for solar lentigines. ... Pay-Per-View - M2 Presswire - HighBeam Research Lightening up: other options.(HQ state of the DEBATE) - Jul 1, 2007 Solage (mequinol, tretinoin; Barrier Therapeutics) outperforms OTC alternatives and is a prescription alternative to hydroquinone, says Zoe Draelos, MD, ... $4.95 - Dermatology Times - ECNext Business Update; Dermatology firm acquires US, Canadian rights to … - Mar 11, 2005 ...announced the acquisition of the US and Canadian rights to Solage (mequinol 2%, tretinoin 0.01%) Topical Solution from Moreland Enterprises Limited. ... Pay-Per-View - Drug Week - Factiva, from Dow Jones BARRIER RETAINS WORLDWIDE RIGHTS TO HYPHANOX. | Article from … - Nov 1, 2005 The company currently markets Solage(r) (mequinol 2%, tretinoin 0.01%) Topical Solution in the U.S. and Canada for the treatment of solar lentigines, ... Pay-Per-View - Biotech Business - HighBeam Research Talk fertility with rheumatic patients.(Across Specialties) | Article... - Jun 1, 2008 Five healthy male patients aged 30-45 years with at least a 1-year history of melasma were instructed to apply a 2% mequinol/0.01% tretinoin ... ... Pay-Per-View - Skin & Allergy News - HighBeam Research Competitors by Product Report - Aug 2, 2008 Products:. Solage (Tretinoin/Mequinol). Allergan, Inc. (AGN) Products:. Avage (Tazarotene) Cream. Johnson & Johnson (JNJ) Products:. Renova (Tretinoin) ... $75.00 - Revere Reports - Revere Barrier's Solage performs well in dark skin types. - Jan 22, 2007 ...safety and tolerability of its Solage (mequinol 2%, tretinoin 0.01%) topical solution, in the treatment of solar lentigines in darker skin types. ... $9.94 - Pharma Marketletter - Alacra Store Press Release: Ventiv Health Announces Marketing Agreement with … - May 2, 2005 The first product, Solage(R) (mequinol 2%, tretinoin 0.01%), is indicated for solar lentigines, commonly known as "age spots". It is the only combination ... Pay-Per-View - PR Newswire - HighBeam Research Finance; Pharmaceutical firm reports loss of $0.62 per share - Apr 1, 2005 By acquiring Solage (mequinol 2%, tretinoin 0.01%) Topical Solution, a patented, prescription product, which we now market in the United States and Canada, ... Pay-Per-View - Drug Week - Factiva, from Dow Jones Stiefel to buy Barrier Therapeutics.(RX/News)(Stiefel Laboratories... - Jul 14, 2008 ...for diaper dermatitis complicated by documented candidiasis; and Solage (mequinol 2%, tretinoin 0.01%) topical solution, for solar lentigines. ... Pay-Per-View - Chain Drug Review - HighBeam Research BARRIER RETAINS WORLDWIDE RIGHTS TO HYPHANOX. - Nov 1, 2005 The company currently markets Solage(r) (mequinol 2%, tretinoin 0.01%) Topical Solution in the US and Canada for the treatment of solar lentigines, ... $4.95 - Biotech Business - ECNext Best practices in: emerging treatment options for postinflammatory … - Oct 1, 2007 Recent clinical investigation of the combination solution of mequinol 2% and tretinoin 0.01% suggests the product might represent a new therapeutic option ... Pay-Per-View - Skin & Allergy News - HighBeam Research Press Release: Barrier Therapeutics to Present at the Roth Capital … - Feb 16, 2005 The Company currently markets Solage(R) (mequinol 2%, tretinoin 0.01%) Topical Solution for the treatment of solar lentigines in the U.S., ... Pay-Per-View - PR Newswire - HighBeam Research Press Release: Barrier Therapeutics to Present Data on Azoline and … - Feb 18, 2005 The Company currently markets Solage(R) (mequinol 2%, tretinoin 0.01%) Topical Solution for the treatment of solar lentigines in the U.S., ... Pay-Per-View - PR Newswire - HighBeam Research Personnel; Pharmaceutical firm names three new additions to commercial... - Mar 18, 2005 ...now that we have acquired the marketed product Solage (mequinol 2%, tretinoin 0.01%) Topical Solution and as we prepare for the launch of Zimycan, ... Pay-Per-View - Drug Week - Factiva, from Dow Jones Finance; Pharmaceutical firm reports loss of $0.62 per share - Mar 28, 2005 By acquiring Solage (mequinol 2%, tretinoin 0.01%) Topical Solution, a patented, prescription product, which we now market in the United States and Canada, ... Pay-Per-View - Health & Medicine Week - Factiva, from Dow Jones |
|
Health Home | Conditions | Cancer | Medications | Surgery | Vaccines The Cancer News Network
COPYRIGHT 2009 CANCERNEWSNETWORK | Privacy |